Cytokinetics Inc.
Late‑stage biotech developing Phase III small‑molecule cardiac and skeletal muscle activators/inhibitors, including omecamtiv mecarbil for heart failure and aficamten for hypertrophic cardiomyopathy, with strategic alliances with Ji Xing and a Japanese licensee.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 498
- HQ: South San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.